What is the 13F Pro Quality Score for CYTK?

13F Pro ranks CYTOKINETICS INC (CYTK) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYTK's current score at https://13fpro.ai/company/CYTK (free sign-up required for the full ranking).

Where does 13F Pro source CYTK data?

All CYTOKINETICS INC fundamentals and ownership data come directly from SEC EDGAR. CYTOKINETICS INC files with the SEC under CIK 1061983. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYTK in?

CYTOKINETICS INC (CYTK) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYTK research updated on 13F Pro?

CYTK's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CYTOKINETICS INC(CYTK)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1061983 CYTK stock profile & AI dashboard →

13F Pro Quality Score

28.1/100

Rank #2,566 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

99.3/100

Profitability

2.0/100

Balance Sheet

2.9/100

Earnings Quality

30.4/100

Free Cash Flow

1.9/100

Institutional Flow

46.8/100

Revenue Scale

11.3/100

Dilution Risk

2.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CYTK Scores 28/100

exact factor attribution · 2026-09-11

CYTK's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.9 pts

99th pct

Institutional flow

-0.2 pts

47th pct

Earnings quality

-2.0 pts

30th pct

Earnings growth

-2.3 pts

4th pct

Shareholder dilution

-2.4 pts

3th pct

Capital efficiency

-4.7 pts

3th pct

Scale

-5.8 pts

11th pct

Profitability

-7.2 pts

2th pct

Free cash flow

-7.2 pts

2th pct

Latest change (2026-08-08): 28 → 18 · ↓ Revenue growth 99→65; ↓ Revenue scale 16→2

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in CYTK

Events flagged as statistical outliers against CYTK's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-08
CYTK quality score dropped 10 points (28→18) on a new filing
View source filing →

CYTK Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CYTOKINETICS INC (CYTK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYTK at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,566 of 2,961 stocks — the bottom half of the AI-ranked universe. CYTK scores in the top quartile across revenue growth (99.3). Areas of concern include free cash flow (1.9) and profitability (2.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CYTOKINETICS INC reports quarterly revenue of $28.6M, net income of $-198.8M, free cash flow of $-164.2M. Top institutional holders of CYTK by reported 13-F value include BlackRock, T. Rowe Price Investment Management, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. CYTK trades on the Nasdaq exchange and files with the SEC under CIK 1061983. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYTK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CYTOKINETICS INC directly from SEC EDGAR. CYTOKINETICS INC's 13F Pro composite quality score has ranged between 7 and 31 since 2021, currently 28.1 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about CYTOKINETICS INC

Quirks, history, and lore behind CYTK — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company headquartered in South San Francisco · focused entirely on muscle biology · listed on Nasdaq.
2
The Numbers
Largely pre-revenue for most of its life, burning cash on R&D · but a late-stage drug candidate drew major partnership deals worth hundreds of millions in potential milestones.
3
The History
Founded around 2001, it spent two decades quietly studying how sarcomere proteins control muscle contraction — a niche so narrow most investors couldn't spell it.
4
The Secret
Its lead program targets cardiac muscle, not skeletal muscle — specifically aiming to help the heart pump harder in patients with heart failure with reduced ejection fraction.
5
The Lore
Its partnership with AstraZeneca on its cardiac myosin activator program put a Big Pharma stamp of approval on a science platform most had slept on for years.
6
The Giveaway
The company's drug omecamtiv mecarbil — and its next-gen cardiac program aficamten for hypertrophic cardiomyopathy — are the reason the word 'cytokinetics' is finally on Wall Street's radar.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$28.6M

Net Income

Q2 2026

$-198.8M

Free Cash Flow

Q2 2026

$-164.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+376.6% YoY

$88.0MFY 2025

FY22 $94.6MFY23 $7.5MFY24 $18.5MFY25 $88.0M

Net Income

-33.2% YoY

$-785.0MFY 2025

FY22 $-389.0MFY23 $-526.2MFY24 $-589.5MFY25 $-785.0M

Operating Income

-14.2% YoY

$-612.3MFY 2025

FY22 $-324.2MFY23 $-496.2MFY24 $-536.2MFY25 $-612.3M

EPS (Diluted)

-24.3% YoY

$-6.54FY 2025

FY22 $-4.33FY23 $-5.45FY24 $-5.26FY25 $-6.54

Total Assets

+1.6% YoY

$1.42BFY 2025

FY22 $1.01BFY23 $824.3MFY24 $1.40BFY25 $1.42B

Total Debt

-54.4% YoY

$287.6MFY 2025

FY22 $650.5MFY23 $649.3MFY24 $631.0MFY25 $287.6M

Op. Cash Flow

-28.8% YoY

$-510.0MFY 2025

FY22 $-299.5MFY23 $-414.3MFY24 $-395.9MFY25 $-510.0M

Free Cash Flow

-33.8% YoY

$-534.8MFY 2025

FY22 $-310.9MFY23 $-415.7MFY24 $-399.8MFY25 $-534.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$88.0M +376.6%	$18.5M +145.3%	$7.5M -92.0%	$94.6M +34.3%	$70.4M +26.2%	$55.8M
Net Income	$-785.0M -33.2%	$-589.5M -12.0%	$-526.2M -35.3%	$-389.0M -80.6%	$-215.3M -69.2%	$-127.3M
Operating Income	$-612.3M -14.2%	$-536.2M -8.1%	$-496.2M -53.1%	$-324.2M -74.0%	$-186.3M -98.3%	$-93.9M
EPS (Diluted)	$-6.54 -24.3%	$-5.26 +3.5%	$-5.45 -25.9%	$-4.33 -54.6%	$-2.80 -42.1%	$-1.97
Total Assets	$1.42B +1.6%	$1.40B +70.0%	$824.3M -18.8%	$1.01B +20.6%	$841.3M +57.6%	$533.8M
Total Debt	$287.6M -54.4%	$631.0M -2.8%	$649.3M -0.2%	$650.5M +1273.4%	$47.4M +2.5%	$46.2M
Operating Cash Flow	$-510.0M -28.8%	$-395.9M +4.5%	$-414.3M -38.3%	$-299.5M -110.2%	$-142.5M -1693.7%	$8.9M
Free Cash Flow	$-534.8M -33.8%	$-399.8M +3.8%	$-415.7M -33.7%	$-310.9M -62.4%	$-191.4M -8975.1%	$-2.1M

Get alerted when CYTK's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CYTOKINETICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYTK

BlackRock, Inc.
$1.7B20,094,362 sh
T. Rowe Price Investment Management, Inc.
$1.6B18,718,498 sh
WELLINGTON MANAGEMENT GROUP LLP
$590.5M6,931,770 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$571.8M6,711,799 sh
STATE STREET CORP
$553.2M6,494,233 sh
VANGUARD CAPITAL MANAGEMENT LLC
$521.2M6,117,515 sh
FMR LLC
$428.7M5,031,782 sh
Avoro Capital Advisors LLC
$425.9M4,999,999 sh
BANK OF AMERICA CORP /DE/
$394.9M4,635,709 sh
GEODE CAPITAL MANAGEMENT, LLC
$316.3M3,712,501 sh

Fund	Value	Shares
BlackRock, Inc.	$1.7B	20,094,362
T. Rowe Price Investment Management, Inc.	$1.6B	18,718,498
WELLINGTON MANAGEMENT GROUP LLP	$590.5M	6,931,770
VANGUARD PORTFOLIO MANAGEMENT LLC	$571.8M	6,711,799
STATE STREET CORP	$553.2M	6,494,233
VANGUARD CAPITAL MANAGEMENT LLC	$521.2M	6,117,515
FMR LLC	$428.7M	5,031,782
Avoro Capital Advisors LLC	$425.9M	4,999,999
BANK OF AMERICA CORP /DE/	$394.9M	4,635,709
GEODE CAPITAL MANAGEMENT, LLC	$316.3M	3,712,501

Companies Similar to CYTK

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

RYTM

RHYTHM PHARMACEUTICALS, INC.

AI score

Very similar · 25 shared holders

Polar Capital Holdings Plc Capital Research Global Investors Siren, L.L.C.

KYMR

Kymera Therapeutics, Inc.

AI score

Very similar · 28 shared holders

T. Rowe Price Investment Management, Inc.Avoro Capital Advisors LLC Capital Research Global Investors

CRNX

Crinetics Pharmaceuticals, Inc.

AI score

Very similar · 18 shared holders

Polar Capital Holdings Plc T. Rowe Price Investment Management, Inc.Siren, L.L.C.

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 33 shared holders

Polar Capital Holdings Plc Frazier Life Sciences Management, L.P.Capital Research Global Investors

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 31 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Polar Capital Holdings Plc Frazier Life Sciences Management, L.P.

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Very similar · 13 shared holders

Deep Track Capital, LP Avoro Capital Advisors LLC Candriam S.C.A.

TNGX

Tango Therapeutics, Inc.

AI score

Very similar · 25 shared holders

RTW INVESTMENTS, LP Holocene Advisors, LP Siren, L.L.C.

AGIO

AGIOS PHARMACEUTICALS, INC.

AI score

Very similar · 9 shared holders

ARMISTICE CAPITAL, LLC ADAR1 Capital Management, LLC Rock Springs Capital Management LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYTK on your watchlist

Track score changes the day CYTOKINETICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYTK a good stock to buy?

13F Pro's AI-powered analysis of CYTOKINETICS INC (CYTK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYTK are available on the CYTK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CYTK is classified as a large company.

Which hedge funds own CYTK?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYTK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CYTOKINETICS INC's investment landscape.